Every briefing, newest first. Filter by sector.
FitLab's Chapter 11 after Nike walked, Xponential's shrinking same-store sales and lowered guidance, and HYROX's near-$700 million PE deal sketch consolidation's two faces: disciplined platforms win, sweeping roll-ups unravel.
Lanserhof's €95 million capital injection funds a global clinic rollout while sleep tech draws Series B money and health systems in three countries begin paying for structured exercise — recovery is becoming a reimbursement-grade service line.
Newly PE-backed HYROX gains World Triathlon governance for Hybrid Racing, opening 177 national federations as potential event operators — a participation flywheel for gyms training hybrid athletes.
Record participation, the widest operator growth base in years and vast emerging-market headroom now collide with intensifying competition and price-sensitive members — 2026 is an execution test, not a demand question.
Innova ranks protein the No. 1 global food-and-drink trend of 2026, with 80% of consumers paying attention to it — and capital is following, with WILDE's $40 million round targeting a $5.5 billion meat-snack market.
Technogym's agentic AI cuts trainers' program-design time by up to 80% on a 38-million-user dataset, Whoop grounds coaching in medical records, and ACSM keeps mobile apps among its top trends — AI is becoming retention infrastructure.
Owners' own survey data puts flexible contracts and hybrid access ahead of price cuts, aggregator channels keep feeding studios incremental revenue — and Xponential's shrinking same-store sales show the cost of standing still.
ACSM's 21st annual survey ranks wearable technology No. 1 for the tenth time, with strength training, healthy aging and mobile exercise apps prominent — consistent validation of the tech-led agenda operators are buying.
Tirzepatide is projected to become the world's best-selling drug in 2026 and the Wegovy pill has passed five million US prescriptions — so operators are rebuilding programming around resistance training and habit-building rather than bracing for churn.
Discovery Vitality will fully fund an Apple Watch or Oura Ring 4 against 24 months of goals, and John Hancock drops monthly payments to zero at 500 points — the wearable is becoming an insurance benefit line.
Peloton's first profitable year — $63 million of net income on $2.446 billion of revenue — and Garmin's record $7.25 billion show connected fitness's survivors are cash machines, even as Peloton's subscriber base keeps shrinking.
Life Time grew Q2 revenue 13.7% to $866.0 million and net income 40.6% — the premium athletic country club model is outrunning the industry median of +10.7% on rate, engagement and mix rather than headcount.
Revenue up 7.1% to $365.2 million with same-club growth coming entirely from rate, a 68% Black Card mix and a $200 million buyback — the value giant's growth engine is now price, not traffic.
Oura postponed a US IPO despite ~90% expected revenue growth and an $11 billion valuation, while Ultrahuman raised $70 million and Whoop sits at $10.1 billion — late-stage capital keeps arriving even as exits stall.
